WAY-261240 is a drug which acts as a potent and selective 5-HT2C receptor agonist, though its affinity at other serotonin receptors has not been disclosed. It produces anorectic effects in animal studies. A large family of related derivatives is known.[1][2][3][4][5][6]

See also

References

  1. ^ Lee J, Jung ME, Lee J (November 2010). "5-HT2C receptor modulators: a patent survey". Expert Opinion on Therapeutic Patents. 20 (11): 1429–55. doi:10.1517/13543776.2010.518956. PMID 20849206. S2CID 32729624.
  2. ^ WO 2006116165, Heffernan GD, Stack GP, Gross JL, Zhou D, Gao H, "Chromane and chromene derivatives and uses thereof", published 2 November 2006, assigned to Wyeth. 
  3. ^ WO 2005044812, Gross JL, Williams MJ, Stack GP, Gao H, Zhou D, "Dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists", published 19 May 2005, assigned to Wyeth. 
  4. ^ WO 2006116158, Zhou D, Stack GP, Gross JL, Gao H, "Benzodioxane and benzodioxolane derivatives and uses thereof", published 2 November 2006, assigned to Wyeth. 
  5. ^ WO 2008052075, Stack GP, Hatzenbuhler NT, Zhou D, "Benzoxazine derivatives and uses thereof", published 2 May 2008, assigned to Wyeth. 
  6. ^ WO 2008052078, Stack GP, Luoni G, Bianchi I, Vallese S, "Benzoxathiine and benzoxathiole derivatives and uses thereof", published 2 May 2008, assigned to Wyeth. 


Allikas: http://en.wikipedia.org/wiki/WAY-261240
No tags for this post.